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Background: Due to ongoing rise in need for care for people with chronic diseases and lagging increase in number
of care providers, alternative forms of care provision and self-management support are needed. Empowering patients
through an online care platform could help to improve patients’ self-management and reduce the burden on the
healthcare system.
Methods: Access to laboratory results and educational modules on diabetes will be offered through a platform for
subjects with type 2 diabetes mellitus treated in primary care. Differences in socio-demographic and clinical
characteristics between subjects expressing interest vs. disinterest to use the platform will be explored. Platform usage
will be tracked and compared. Patient satisfaction and quality of life will be measured by validated questionnaires and
economic analyses will be performed.
Discussion: This study is designed to assess the feasibility of use of an online platform in routine primary healthcare
for subjects with type 2 diabetes mellitus in the Netherlands, and to study effects of use of the platform on treatment
satisfaction, quality of life and clinical parameters. Although providing access to a online platform is not a novel
intervention, usage and effects have not yet been studied in this patient population.
Trial registration: Trial registration: NCT01570140.
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TelehealthBackground
Worldwide a dramatic increase is seen in the prevalence
of diabetes. In 2007, the prevalence of diabetes in The
Netherlands was estimated to be 740,000, while in a
conservative estimate this is expected to rise to over
1,300,000 in 2025, of which more than 90% will have
type 2 diabetes mellitus (T2DM) [1,2]. At the same time,
the increase in number of care providers is lagging. This
inevitably will result in an actual decrease in available
face-to-face time for contacts between patients and care* Correspondence: y.roelofsen@isala.nl
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unless otherwise stated.providers. This necessitates development of alternative
forms of treatment and support of patients’ needs and
self-management abilities beyond current situation and
possibilities [2].
One possibility for reducing workload is increasing pa-
tients’ participation in their own care by promoting
knowledge regarding their chronic disease(s) and in-
sights in their own situation. Improving online access to
reliable information through promoting use of an online
platform may help to support such goals [3], but may
also result in reducing workload for caregivers. Further-
more, by creating patient profiles, more specifically tai-
lored educational and training can be offered. Personalral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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viders will also add value. Access to credible health
information and personal health data may potentially
lead to better disease management and improvement of
health. Also, collaborative disease tracking may decrease
communication barriers between patients and caregivers.
This may lead, in turn, to better understanding, more
self reliance and promoting taking responsibility [3],
with hopefully and eventually lower costs.
Large programs have been started and results have
been analysed in the past decades (resulting in decidedly
mixed results), such as the Whole System Demonstrator
(WSD), to study effects of telehealth and telecare [4] and
a study by Kennedy et al. on implementation of self-
management support [5]. However, to see some of the
positive study results translated into (cost) effective use
of e-Health in routine general practice seems to be quite
a challenge up to now [6]. In an effort to further explore
opportunities and barriers, the current study aims to
provide data access and education through an interactive
care platform to T2DM patients in primary care in The
Netherlands.
The use of this care platform will be offered as part of
the e-Vita research program, in which a care platform
will be implemented and studies in various regions of
The Netherlands. Six sub-studies will be performed,
three of which are in patients with different chronic ill-
nesses: T2DM, chronic obstructive pulmonary disease
(COPD) and/or chronic heart failure (CHF). The fourth
study concentrates on cost-effectiveness of these inter-
ventions and will be performed by the Julius Center in
Utrecht. The fifth study will assess determinants of plat-
form usage, by using methods developed by the Center for
eHealth Research and Disease Management, Department
of Psychology, Health and Technology, University of
Twente, Enschede. The sixth study is part of the study
in T2DM patients and is performed by the Department
of Medical Psychology, VU University Medical Center,
Amsterdam.
The presented study is performed in T2DM patients
in the Netherlands, treated in primary care. Patient em-
powerment is strived for by offering the possibility to
track laboratory results based on the yearly check-ups,
as well as offering educational modules to start a self-
chosen process of lifestyle intervention through the plat-
form. Even small improvements in lifestyle may on longer
term result in moderate to large changes in self-reported
dietary and physical activity behaviours that can result in
(cost-effective) improvements in health related measure-
ments (adiposity, blood pressure and lipid levels) [7,8].
Other results may be improvements in patients’ health re-
lated quality of life (HRQoL) [9], which in itself is an inde-
pendent predictor of mortality in patients with T2DM
[10,11]. The earlier mentioned study performed by the VUUniversity Medical Center is a randomized controlled trial
nested within the T2DM study, comparing effects of on-
line coaching vs. no coaching of a self-management sup-
port module on self-reliance [12].Objectives e-VitaDM
This study will investigate the hypothesis that use of a
care platform and its educational content by T2DM pa-
tients will positively influence perceived quality of life,
wellbeing and degree of self-reliance [13-16]. Also, pa-
tients’ opinion regarding received care will be assessed
[17,18]. Furthermore, the influence of platform use on
clinical parameters, like glycaemic control, will be inves-
tigated. Besides direct benefits for patients themselves,
e-health facilities could result in reduction of medical
care utilization, less workload for care providers and de-
crease of costs of care.Objectives ZODIAC
All patients in the study will also be assessed in a long-
term follow-up study for at least the next ten years. This
prospective observational study should be considered
the continuation of the Zwolle Outpatient Diabetes
Project Integrating Available Care (ZODIAC) started in
1997 [19-25]. It will assess the effects of clinical parame-
ters and quality of life on micro- and macrovascular
complications and mortality. In addition, it will address
relevant questions in relation to present routine of dia-
betes care by adding more up-to-date data in comparison
with the initial phase of the ZODIAC project.Methods
Study design
A prospective observational study of patients volunteer-
ing to use the interactive care platform (e-VitaDM),
within the ZODIAC study (see Figure 1). Nested in this ob-
servational study a randomized controlled trial is planned
testing coaching vs. non-coaching of a self-management
support module (see Figure 2) [12].
Study population
The included sample consists of patients with T2DM
treated in primary health care in the Drenthe-region of
The Netherlands as part of the shared care initiative of
the Care Group Drenthe (CGD). Some specific
inclusion- and exclusion criteria have been formulated:
Inclusion criteria
Patients can participate when they are diagnosed with
T2DM (ICPC T90.2), with the GP defined as main care
provider, when they are part of the Drenthe shared care
initiative, and when they are aged ≥18 years.
Figure 1 Patient flow.
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There are no exclusion criteria for the cohort study
(ZODIAC). For the intervention study (e-VitaDM) ex-
clusion criteria are:
– Not participating in the shared care initiative
– Mental retardation or psychiatric treatment for
schizophrenia, organic mental disorder or bipolar
disorder currently or in the past
– Insufficient knowledge of Dutch language to
understand the requirements of the study and/or the
questions posed in the questionnaires
– Life expectancy <1 year due to malignancies or
other terminal illnesses
– Cognitive impairment, including dementia, that
interferes with trial participation
– Any condition that the investigator of coordinating
investigator feels would interfere with trial
participation or evaluation of results
Setting
The CGD is one of the care groups connected to our
Diabetes Centre for benchmarking and study purposes
for years. It is the largest care group in The Netherlands,
including over 500,000 subjects and over 200 GP’s, divided
over 110 practices. 52 out of the 110 general practices
agreed to participate in the e-VitaDM/ZODIAC study. In
these practices approximately 8300 T2DM patients were
treated in 2011.
In line with clinical guidelines, patients in CGD are
seen four times a year, of which one visit is the annual
check-up. All patients with T2DM fulfilling the inclusionFigure 2 RCT nested in e-VitaDM study.criteria, will be asked to participate in the prospective
observational cohort study (ZODIAC) three months
before their annual check-up. They are also informed
about the possibility to use the care platform (e-VitaDM).
Patients who express interest in using the platform
are registered on the platform by their primary care
nurse (PN) and will be included in the e-VitaDM
study. The PN’s are trained to offer their T2DM pa-
tients information and guidance with the use of the
platform and its educational content. Participants will
be able to use the platform after their written consent
and registration by their PN.
Study duration
The inclusion period will last one year and the follow-up
period for the e-VitaDM part will last one year and three
months. This will result in a study duration of two years
and three months. A complete set of data of an individual
person (clinical measures and questionnaires) is available
at the annual check-up and at one year. Figure 3 shows
the individual timeline.
Information on interactive care platform
A selection of DM-related health measurements as per-
formed at the annual check-up will be provided on the
platform to the individual participant, accompanied
with an explanation of each item. These measurements
are available from 2009 onwards, so patients will see
their results over some years. Results will be displayed
textually as well as graphically, showing individual values
as well as the development of values over time (see
Additional file 1).
Figure 3 Individual timeline.
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sented to the participant based on gender, age and actual
laboratory results and clinically important measurements
(e.g. HbA1c and blood pressure), using pre-programmed
algorithms. In this way, a patient specific profile is cre-
ated to allow a more tailored approach in offering edu-
cation. After presentation of specific information to the
patient, understanding of this information will be tested
by a few questions. If patients allow, their care provider
will receive an automated message in the electronic pa-
tient record, indicating that the participant has com-
pleted an educational module. This information can be
used as input during the next visit with the GP or PN.
In addition, participants can improve their health by
setting goals and actions as part of the self-management
module. The development of the self-management mod-
ule in e-Vita is based on the Health Action Process
Approach (HAPA) model of behaviour change and the
Proactive Interdisciplinary Self-Management (PRISMA)
course [12].
The platform is designed with emphasis on making it
suitable and available for all T2DM patients. From the
start, special focus groups of caregivers and caretakers are
actively involved in designing and testing of this platform.
The platform is reached through an HTTPS-connection
and a multi-factor authentication. Development and host-
ing of the platform is based on NEN-procedure 7510,
ISO 27001, Security Access Layer (SAL), Personal DataTable 1 Overview and time schedule for data to be collected
Patients using platfo
T-1 T0
Patient profile X
Use of platform
EQ-5D, EQ-VAS, WHO-5, PAID-5, X
SDSCA X
Europep
Laboratory/clinical measures X
Medication care utilization X
Micro- and macrovascular complications X
Mortality, assessed by PN/GP
Number of encounters with care providers
Mortality, CBS, GBAProtection Act (in Dutch: Wet Bescherming Persoonsge-
gevens (WBP)) and National Cyber Security Centre’s ICT
Security Guidelines for web applications part 1 and 2, in
which a code for protection of information is determined.
Measurements
Table 1 shows an overview and time schedule for data to
be collected in the intervention study (e-VitaDM) and
the observational cohort study (ZODIAC). The collec-
tion of data follows NEN-procedure 7510 and all sub-
standards based on the ISO 27000 series. In addition, all
identifiable personal information will be encrypted in ac-
cordance with the Rijndael algorithm.
The baseline assumption is that ≥90% will participate
in the long-term study (ZODIAC), as was our experience
in the earlier ZODIAC-study, but that no more than
20% of the patients will express interest in the e-Vita
platform (e-VitaDM).
Quality assessment lists
All patients with T2DM participating in the observa-
tional cohort study (including those who are not inter-
ested in the platform) are asked to fill in a range of
validated questionnaires to measure perceived quality of
life (EQ-5D) [13], well-being (WHO-5) [14], diabetes-
distress (PAID-5) [15], diabetes self-care behaviour
(SDSCA) [16] and perceived quality of received care
(Europep) [17,18]. Additional questions about coffee/tearm (e-VitaDM) Patients in cohort only (ZODIAC)
T1 T2 T-1 T0 T1 T2
X
X X
X X X X X
X X X
X X X
X X X X X
X X X
X X
X X
X X
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background are included as well. Questionnaires are
filled in at different time points (see Figure 3).
Clinical data gathering
Besides the questionnaires, clinical measures as de-
scribed in the NHG/NAD core set of parameters will be
collected (see Additional file 2). These measures are
already being collected by the patients’ GP and PN dur-
ing their annual check-up and are routinely sent to our
Diabetes Centre for benchmark en study purposes. After
informed consent of included patients, clinical data will
be combined with the results of the collected question-
naires to assemble a complete and anonymized dataset.
Data regarding micro- and macrovascular complications
and mortality will be gathered from patient records from
the GP. Mortality will also be checked by using data from
Central Statistical Office (in Dutch: Centraal Bureau voor
Statistiek (CBS)) or Municipal Administration (in Dutch:
Gemeentelijke Basisadministratie (GBA)).
Data on actual contacts
Data on actual amount of patient – care provider con-
tacts will be retrieved in a subpopulation. The availabil-
ity of these data greatly depends on the information
system used by primary care givers. Since five different
systems (each with their own strengths and limitations)
are used in the Drenthe-region, one specific information
system (Medicom, which is used by 8 general practices)
is chosen for detailed analysis on this subject. This sys-
tem is not only known for its reliability of structured data
entry, data transport and medication information, but es-
pecially for its reliable registration of number of encoun-
ters with care providers and number of hospitalizations.
Further sample collection and storage
In addition to the blood drawn as part of the annual
check-up, two extra tubes of blood (10 ml serum and
10 ml plasma) will be collected in consenting subjects
and frozen for future research on novel biomarkers.
Assessment of determinants of platform use
In order to find out how the platform is used in practice,
log-data will be used to track individual use of the plat-
form over time (number of log-ons, time spent per ses-
sion and used elements). These log-files will be used for
identifying user profiles and they will provide insight
about adherence to the platform, usage patterns and
what elements of the platform are used. This informa-
tion provides insight in how the platform (both content
and system) matches with the users [26]. In addition,
specific questionnaires will be sent to all patients who
expressed their interest in using the e-Vita platform, ir-
respective of actual use. These questionnaires includeTIPI [27], PAM-13 [28], short version of PII [29], ques-
tions about trust [30], questions about general use of the
Internet and questions about use of and satisfaction with
the platform [31].
Furthermore, care providers will be interviewed in a
semi-structured way to assess possible care provider re-
lated factors influencing patient’s platform use.
Primary and secondary endpoints
The quality assessment in terms of EQ-5D is the pri-
mary objective in this study. A clinically relevant differ-
ence of 0.074 in the EQ-5D index score is predefined
[32]. Secondary endpoints are well-being as assessed by
the WHO-5 questionnaire, diabetes-distress as assessed
by the PAID-5, self reliance as assessed by the SDSCA,
quality of delivered care as assessed by the Europep and
clinical parameters.
Statistical analyses
Analyses in intervention study (e-VitaDM)
To evaluate differences in target variables over time and
within groups, we will use the linear mixed model for re-
peated measures. Variables measured after 6 and after
12 months will be used as within-subjects variables.
Baseline variables will be used as covariates. Making use
of the platform or not will be used as a between-subjects
factor. In case of differences between groups on relevant
variables, these variables will be added as a covariate in
the multivariable analyses.
Additional analyses in larger prospective cohort study
(ZODIAC-40)
Cox proportional hazard models will be used to investi-
gate the association between (bio)marker levels and
future events (microvascular complications, macrovas-
cular complications and mortality) with adjustment for se-
lected confounders.
Harrell’s C statistic, a rank based measure will be used
to compare how well the presence of the marker in the
different models used, predicts the outcome of interest.
The need for additional analyses, i.e. measures of dis-
crimination improvement (integrated discrimination im-
provement, IDI, and net reclassification improvement,
NRI) will be decided for each marker separately.
Medical ethical committee
The current study has been reviewed and approved by
the Medical Ethical Committee of Isala.
Discussion
Offering T2DM patients information, education and
insight in health data through internet is not new at all.
However, to our knowledge, in The Netherlands there
has never been a study of the proposed scale towards
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platform as proposed in the e-Vita research program.
Furthermore, part of the assessment includes structural
measurements of perceived quality of life and care.
At the start of e-VitaDM study the actual content of
the care platform is limited to insight in DM-related
health data of an individual patient and education. In
this ongoing study, new modules will be added especially
concentrating on educational content. The development
of further educational content is crucial, not only to fur-
ther enhance active use of the platform, but also to as-
sess the effects of new additions and improvements in a
continuous cycle using focus groups in each step. The
creation of content, including 2-way communication,
e-contact and e-consult, during this study and keep-
ing track of its fit with patients’ needs is not the pri-
mary focus in this research, but nevertheless has to
be taken into account, not only in striving for the lar-
gest possible effect, but also in analyzing the collected
data. At the moment, communication between PN’s and
patients is limited to automated messages in the electronic
patient record when patients allow this in case of complet-
ing educational modules. The platform does not provide
an extensive 2-way communication tool (e.g. exchange
messages) on top of the automated messages, but develop-
ments concerning this are already ongoing.
A previous study by the British National Health System
proves that unless personal electronic health records align
closely with people’s attitude, self management practices,
identified information needs and the wider care package
(including organizational routines and incentive structures
for clinicians), the risk that they will be abandoned or not
adopted at all is substantial [33].
The WSD shows that telehealth is associated with
lower mortality and emergency admission rates [34], but
also that telehealth did not improve quality of life or psy-
chological outcomes for patients with COPD, T2DM or
CHF over 12 months [35]. In terms of cost-effectiveness,
the WSD shows that the QALY gain by patients using tele-
health in addition to usual care was similar to that by pa-
tients receiving usual care only, and total costs associated
with telehealth were higher [6]. However, generalizability
of the WSD-study results in terms of diagnosis, relative
risks and outcomes to the Dutch situation in uncertain.
Additional files
Additional file 1: Clinical measurements provided on the platform
are the following, as also can be seen in the figure below: HbA1c,
blood pressure, lipid profile, Cockcroft, alb/kreat ratio, smoking,
length, weigth and BodyMass Index (BMI).
Additional file 2: Diabetes Core Set. The core set describes a minimum
set of parameters, which should be digitally registered by care providers for
the purpose of providing care for T2DM patients. These data are used by care
providers and patients in the communication and they serve to a largeextent as a basis for the calculation of indicators. The table shows a summary
of the data collected for this study, a detailed description can be found at
http://www.actieprogrammadiabetes.nl/images/stories/downloads/
ondersteuningsaanbod/e-Diabetes_Mellitus_kernset_samenvatting.pdf.
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